Hassan Ahmed A, Signorile Marisa, McNamee Sophie, Chaturvedi Rajiv, Benson Lee
Department of Pediatrics, Labatt Family Heart Centre, Division of Cardiology, The Hospital for Sick Children, Temertry Faculty of Medicine, University of Toronto, Toronto, Canada.
Ted Rogers Computational Program, Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, UHN, Toronto, Canada.
Catheter Cardiovasc Interv. 2025 Aug;106(2):765-771. doi: 10.1002/ccd.31605. Epub 2025 May 20.
The persistently patent arterial duct accounts for ~12% of congenital heart lesions. Untreated, it may result in heart failure due to volume loading of the left heart, pulmonary hypertension, and infective endarteritis. Percutaneous device closure is the preferred occlusion technique, with the standard approach consisting of femoral artery access for angiography and venous access for device delivery (AA). A venous-only strategy (VA) for angiography and device delivery can also be employed.
We hypothesized that VA would eliminate the need of arterial entry, reduce procedure times and radiation exposure compared to standard AA.
This is a retrospective cohort study of isolated arterial duct device closure at the Hospital for Sick Children from January 1, 2011, through December 31, 2022. Exclusions included premature neonates, children requiring arterial access for monitoring, and those who underwent other procedures. Children were categorized based upon initial access determined by operator preference into VA or AA groups.
The cohort consisted of 405 children, 252 (62.2%) females, with a median age of 3.1 years (IQR 1.30-5.84), median weight 13.2 kg (IQR 9.0-19.5), and duct diameter of 2.9 mm (IQR 2.0-3.5) with no significant differences between the groups. Type A ducts were more frequent in the AA group (90% vs. 72%). The VA group included 106 children, of which 14 (13.2%) required AA conversion for angiography due to complex ductal anatomy, to assess device position before release, but remained in the VA group for analysis. Children in the VA group had lower dose area product (DAP) (p < 0.001), fluoroscopy times (p = 0.025), contrast volumes (p < 0.001), procedure times (p < 0.001), and recovery room lengths of stay (LOS) (p < 0.001). Six (5.7%) VA children required admission compared to 44 (14.7%) in the AA group (p = 0.015) with no difference in reintervention rates. Weighted regression analysis showed VA was associated with reduced admission likelihood (OR: 0.354 [0.131, 0.822], p = 0.024), DAP (coef -126.4 [-213.3, -39.4], p = 0.004), and contrast volumes (coef 31.2 [-36.6, -25.9], p < 0.001) compared to AA.
Venous-only access was associated with lower DAP and recovery room LOS. Additionally, VA was associated with a lower likelihood of admission with no difference in reintervention rates, suggesting procedural safety. These findings support the consideration of VA as a preferred approach for appropriate cases.
动脉导管持续未闭占先天性心脏病病变的约12%。若不治疗,可能因左心容量负荷、肺动脉高压和感染性动脉内膜炎导致心力衰竭。经皮装置封堵是首选的闭塞技术,标准方法包括经股动脉穿刺进行血管造影以及经静脉穿刺输送装置(AA法)。也可采用仅经静脉的策略(VA法)进行血管造影和装置输送。
我们假设与标准AA法相比,VA法可避免动脉穿刺,减少手术时间和辐射暴露。
这是一项对2011年1月1日至2022年12月31日在病童医院进行的孤立性动脉导管装置封堵术的回顾性队列研究。排除标准包括早产儿、需要动脉穿刺进行监测的儿童以及接受其他手术的儿童。根据操作者偏好确定的初始穿刺途径,将儿童分为VA组或AA组。
该队列包括405名儿童,其中252名(62.2%)为女性,中位年龄3.1岁(四分位间距1.30 - 5.84),中位体重13.2千克(四分位间距9.0 - 19.5),导管直径2.9毫米(四分位间距2.0 - 3.5),两组之间无显著差异。AA组中A型导管更为常见(90%对72%)。VA组包括106名儿童,其中14名(13.2%)因导管解剖结构复杂,在释放装置前需要转换为AA法进行血管造影以评估装置位置,但仍留在VA组进行分析。VA组儿童的剂量面积乘积(DAP)较低(p < 0.001)、透视时间较短(p = 0.025)、造影剂用量较少(p < 0.001)、手术时间较短(p < 0.001)以及恢复室住院时间较短(p < 0.001)。VA组有6名(5.7%)儿童需要住院,而AA组有44名(14.7%)(p = 0.015),再次干预率无差异。加权回归分析显示,与AA法相比,VA法与住院可能性降低(比值比:0.354 [0.131, 0.822],p = 0.024)、DAP降低(系数 -126.4 [-213.3, -39.4],p = 0.004)以及造影剂用量降低(系数31.2 [-36.6, -25.9],p < 0.001)相关。
仅经静脉穿刺与较低的DAP和恢复室住院时间相关。此外,VA法与较低的住院可能性相关,再次干预率无差异,表明手术安全性良好。这些发现支持在合适的病例中将VA法作为首选方法。